• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Psyence Biomedical Ltd.

    5/6/25 4:01:32 PM ET
    $PBM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PBM alert in real time by email
    6-K 1 ea0241127-6k_psyence.htm 6-K

     

     

    UNITED STATES

     

    SECURITIES AND EXCHANGE COMMISSION

     

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THESECURITIES EXCHANGE ACT OF 1934

     

    For the month of May 2025

     

    Commission File Number: 001-41937

     

    Psyence Biomedical Ltd.

     

    (Translation of registrant’s name into English)

     

    121 Richmond Street West
    Penthouse Suite 1300
    Toronto, Ontario M5H 2K1

     

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    X Form 20-F ☐ Form 40-F

     

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
    99.1   Press Release

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

    Dated: May 6, 2025

     

     

    Psyence Biomedical Ltd.  
         
    By: /s/ Neil Maresky  
    Name: Dr. Neil Maresky  
    Title: Chief Executive Officer and Director  

     

     

    Get the next $PBM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PBM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PBM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Psyence Biomedical Ltd.

      SC 13G - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

      12/13/24 9:16:01 AM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

      SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

      12/9/24 1:36:43 PM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Psyence Biomedical Ltd.

      SC 13G/A - PSYENCE BIOMEDICAL LTD. (0001985062) (Subject)

      12/4/24 4:38:27 PM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Psyence Biomed Further Strengthens Scientific Advisory Board with Appointment of Dr. Dan J. Stein

      Appointment adds significant clinical and scientific expertise in the field of psychedelic-based therapiesNew York, New York--(Newsfile Corp. - March 18, 2025) - Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it has expanded and further strengthened its Scientific Advisory Board (SAB) with the appointment of Dr. Dan J. Stein, a recognized leader in the field of psychopharmacology. He is the Professor and Chair of the Dept of Psychiatry and Mental Health at the University of Cape Town (UCT) and Director of the South African Medical Research Council (MRC) Unit on Risk & Resilience in Mental Disorders. Dr. Stein joins Dr. Albert Garcia-Romeu (Chair

      3/18/25 8:30:00 AM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board

      NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it will work closely with Albert P. Garcia-Romeu, Ph.D., to chair and develop its newly created Scientific Advisory Board (SAB). Dr. Garcia-Romeu is a leading psychedelics researcher currently serving as Associate Professor in the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, as well as Associate Director, Johns Hopkins Center for Psychedelic and Consciousness Research and the Susan Hill Ward Professor in Psychedelics and Consciousness. He is a highly sought after speaker on the therapeutic potential of p

      2/26/25 8:00:00 AM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Psyence Biomed Announces Closing of $2.0 Million Private Placement

      NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 1,000,000 common shares (or pre-funded warrants in lieu thereof), series A common warrants to purchase up to 1,000,000 common shares and short-term series B common warrants to purchase up to 1,000,000 common shares at a purchase price of $2.00 per common share (or per pre-funded warrant in lieu thereof) and accompanying series A common warrant and short-term series B common warrant. The series A common warrants and short-term series B common warrants hav

      12/27/24 4:05:35 PM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBM
    Leadership Updates

    Live Leadership Updates

    See more
    • Psyence Biomed Names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory Board

      NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that it will work closely with Albert P. Garcia-Romeu, Ph.D., to chair and develop its newly created Scientific Advisory Board (SAB). Dr. Garcia-Romeu is a leading psychedelics researcher currently serving as Associate Professor in the Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, as well as Associate Director, Johns Hopkins Center for Psychedelic and Consciousness Research and the Susan Hill Ward Professor in Psychedelics and Consciousness. He is a highly sought after speaker on the therapeutic potential of p

      2/26/25 8:00:00 AM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq

      NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced the voting results for each of the matters presented at the Company's annual and special meeting of shareholders held on November 12, 2024 (the "Meeting"). Shareholders were represented in person or by proxy at the meeting holding 21,877,200 common shares, representing approximately 43.5% of Psyence Biomed's 50,334,170 issued and outstanding common shares as of October 10, 2024, the record date for the Meeting. At the Meeting, a total of five resolutions (the "Resolutions" and each a "Resolution") were submitted to and approved by the Company's shareholder

      11/12/24 4:30:00 PM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant

      Clairvoyant currently executing a fully randomized multi-country Phase IIb clinical trial evaluating a synthetic psilocybin candidate as a potential therapeutic for Alcohol Use Disorder (AUD) Topline data from the ongoing Phase IIb AUD study anticipated in early 2025 NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence Biomed" or the "Company") today announced that the Company has entered into a conditional binding term sheet with privately-held Clairvoyant Therapeutics Inc ("Clairvoyant"), a clinical-stage developer of psilocybin-based therapeutics based in Canada, for the proposed acquisition by Psyence Biomed of 100% of the shareholdings

      9/6/24 7:30:00 AM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBM
    SEC Filings

    See more
    • SEC Form 6-K filed by Psyence Biomedical Ltd.

      6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

      5/6/25 4:01:32 PM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Psyence Biomedical Ltd.

      6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

      4/23/25 4:26:27 PM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Psyence Biomedical Ltd.

      6-K - PSYENCE BIOMEDICAL LTD. (0001985062) (Filer)

      4/11/25 4:00:12 PM ET
      $PBM
      Biotechnology: Pharmaceutical Preparations
      Health Care